KalVista Pharmaceuticals (KALV) Projected to Post Earnings on Thursday

Key Points

• KalVista Pharmaceuticals is set to release its Q1 2026 earnings on September 4th, with analysts predicting a loss of ($0.91) per share and revenue of $1.9680 million for the quarter.
• Following a recent earnings miss, analysts have projected an average loss of $4 EPS for the current fiscal year and $3 EPS for the next fiscal year, while the company's stock has a consensus rating of "Buy" with an average price target of $26.29.
• Insider trading activity revealed that CEO Benjamin L. Palleiko sold 32,979 shares of the stock, reducing his ownership by 8.19%, while several hedge funds have also increased their stakes in KalVista Pharmaceuticals recently.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, September 4th. Analysts expect KalVista Pharmaceuticals to post earnings of ($0.91) per share and revenue of $1.9680 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earningoverview page for the latest details on the call scheduled for Tuesday, September 9, 2025 at 4:00 PM ET.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the business earned ($1.07) EPS. On average, analysts expect KalVista Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $13.59 on Thursday. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $16.32. The company has a 50 day moving average price of $13.45 and a 200 day moving average price of $12.40. The firm has a market capitalization of $684.12 million, a price-to-earnings ratio of -3.68 and a beta of 0.05.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on KALV shares. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. Leerink Partners raised their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. Finally, HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.29.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer owned 369,595 shares in the company, valued at $5,798,945.55. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,942 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the sale, the insider directly owned 119,841 shares in the company, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,710 shares of company stock valued at $880,764. Corporate insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company boosted its holdings in KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company's stock valued at $165,000 after purchasing an additional 818 shares during the period. BNP Paribas Financial Markets boosted its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company's stock valued at $615,000 after purchasing an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after purchasing an additional 2,939 shares during the period. Finally, Creative Planning grew its stake in KalVista Pharmaceuticals by 20.0% during the second quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company's stock worth $377,000 after buying an additional 5,573 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.